The COVID-19 pandemic has prompted pharma companies to collaborate with key technology providers to develop tools that can reduce turnaround time and ensure participant safety. Certain suppliers have expanded their digital clinical trials capabilities to ensure research continuity.
Most organizations use different combination of technologies to achieve a smooth translation workflow. Deploying advanced Machine translation solutions such as AI-powered MT and light post-editing services can be an effective solution to reduce the time and cost without compromising quality.
COVID-19: Assess impact on your suppliers and ensure business continuity with Beroe’s WIRE
(World Instant Risk Exposure)